The immune system works to protect a person from illness by fighting foreign invaders like viruses and bacteria. It can also recognize harmful changes happening inside the body, like the formation of ...

The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on Cellectis‘ Phase 1 trials of UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) ...

AstraZeneca’s Imfinzi (durvalumab) significantly lengthened the time it took for a patient’s non-small cell lung cancer to progress after chemotherapy and radiation, a Phase 3 clinical trial showed.

Viruses, like the flu virus, try to enter the cells in our body because they need a host to survive. Once inside, the virus begins to use the “machinery” of the cell to make copies of itself, ...

PD-1 is an immune checkpoint protein that prevents T-cells from attacking healthy cells. Healthy cells produce a protein called PD-L1 that binds to PD-1, inactivating T-cells. But some tumors have ...

The U.S. Food and Drug Administration (FDA) has approved Imfinzi (durvalumab), in combination with standard chemotherapy, as an initial treatment of people with extensive-stage small cell lung cancer ...

BMS 986178 is an immunotherapy, so it does not directly act on cancer cells but instead boosts the immune response to encourage the body to fight a tumor. It is a monoclonal antibody, a protein that ...

Non-small cell lung cancer (NSCLC) patients with PD-L1 protein in their tumors lived significantly longer when treated with the immunotherapy Keytruda (pembrolizumab) than standard platinum-based ...

A planned safety review of a Phase 2 trial evaluating MDNA55 to treat glioblastoma has shown that the drug, developed by Medicenna Therapeutics is safe to deliver precisely into a patient’s tumor, ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common ...

The U.S. Food and Drug Administration (FDA) has suspended two Phase 1 trials assessing Cellectis’ CAR T-cell therapy UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell ...

First-line treatment with a combination of Yervoy (ipilimumab) and Keytruda (pembrolizumab) failed to prolong survival and delay disease progression in patients with advanced non-small cell lung ...